Lilly Unveils Historic $3.5 Billion Manufacturing Investment in Pennsylvania for Next-Gen Weight-Loss Medicines
Eli Lilly and Company has announced a historic $3.5 billion investment to establish a state-of-the-art manufacturing campus in Fogelsville, Pennsylvania. As the largest life sciences project in the Commonwealth’s history, this facility will be dedicated to producing next-generation injectable medicines, including the investigational triple hormone receptor agonist retatrutide. The project is set to create 850 high-value jobs and solidify the Lehigh Valley as a premier global hub for pharmaceutical innovation and domestic supply chain resilience.
